CONTINUING EDUCATION:
RN, NP:  .75 CE Credit

Recorded Date:  April 11, 2015 (as part of the 2015 PCNA annual symposium in Anaheim)
Original Posting Date: October 30, 2015
Content Reviewed  Date: February 2017

COURSE OVERVIEW:

This presentation provides the latest on the evidence and the guidelines regarding the safety of postmenopausal hormone therapy (HT) in treating menopausal symptoms and its role in CVD risk reduction.

AUDIENCE:
Nurses, advanced practice nurses, and other healthcare providers interested in the prevention and management of cardiovascular disease.

FACULTY DISCLOSURES:
The faculty members have declared no commercial relationships related to the content of this presentation.

COST:
This online educational activity is offered free of charge.

PARTICIPATION IN THE ACTIVITY AND RECEIPT OF CERTIFICATE OF CREDIT:
View the course materials; complete the post-test (you can take the post-test more than once if needed to achieve a passing score of 75%) and online evaluation form at the end of the activity, and print your CE certificate.

ACCREDITOR:
This educational activity is provided by the Preventive Cardiovascular Nurses Association (PCNA). PCNA is accredited by the American Association of Nurse Practitioners (AANP) as an approved provider of Nurse Practitioner continuing education, provider number 030602. 

Please note that if you received credit for attending the 2015 PCNA Annual Symposium in Anaheim, you will be unable to claim credit for the on-demand sessions that were recorded there.  

Describe an evidence-based approach to shared decision making for the clinician and perimenopausal patient considering menopausal hormone therapy or selective estrogen receptor modulators.